Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS ANNOUNCES WARRANT TERMS AMENDMENT

Defence Therapeutics Inc. has amended the terms of a total of 800,000 common share purchase warrants originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months, and the exercise price will be repriced at 75 cents per common share as follows.

None of the warrants have been exercised as of the date hereof. All other terms of the warrants will remain unchanged. In accordance with the requirements of the Canadian Securities Exchange, the terms of any warrants issued as compensation warrants or as finder warrants are not eligible for amendment. The amendments are subject to the final approval of the CSE.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.